Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Open Access
- 26 June 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (13), 4579
- https://doi.org/10.3390/ijms21134579
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still the main therapeutic approach for this subgroup of patients, therefore, progress in the treatment of TNBC remains an important challenge. Data derived from molecular technologies have identified TNBCs with different gene expression and mutation profiles that may help developing targeted therapies. So far, however, only a few of these have shown to improve the prognosis and outcomes of TNBC patients. Robust predictive biomarkers to accelerate clinical progress are needed. Herein, we review prognostic and predictive biomarkers in TNBC, discuss the current evidence supporting their use, and look at the future of this research field.Keywords
This publication has 288 references indexed in Scilit:
- Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cellsCellular Signalling, 2013
- Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast CancerClinical Breast Cancer, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasisNature, 2012
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Differential Expression of PTEN-Targeting MicroRNAs miR-19a and miR-21 in Cowden SyndromeAmerican Journal of Human Genetics, 2008
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007